-
Dimetridazole Workflows for MDR Assays
2026-08-19
Dimetridazole supports more than routine antimicrobial screening: it can be evaluated as a membrane-active partner in multidrug-resistant bacterial assays, a quorum sensing inhibitor, and an analytical sensing target. This workflow connects checkerboard synergy testing with membrane, fatty-acid, biofilm, and infection model research while emphasizing strain-specific optimization and laboratory safety.
-
Kidney Progenitor Assembloids for Disease Modeling
2026-08-19
Huang and colleagues developed spatially patterned mouse and human kidney progenitor assembloids that more faithfully reproduce nephron–collecting duct organization, maturation, and selected kidney functions than conventional organoids. Their genome-edited PKD2−/− human assembloids also model cyst formation and interactions among cyst epithelium, stroma, and macrophages, providing a higher-fidelity platform for kidney disease research.
-
A-769662: An Assay-First AMPK Guide
2026-08-18
A-769662 is a reversible AMPK activator for studying energy metabolism, lipid synthesis, and autophagy interpretation. This assay-first guide explains how to separate direct AMPK effects from downstream stress responses using the latest mechanistic evidence.
-
Methyl-β-cyclodextrin: Membrane Workflow Guide
2026-08-18
Methyl-β-cyclodextrin (SKU C6939) provides a practical reagent for extracting cholesterol and other lipids from cellular membranes when researchers need to examine membrane organization, fluidity, or cholesterol-sensitive signaling. It is intended for controlled scientific workflows only, not diagnostic, clinical, or therapeutic use, and solutions should be prepared and used promptly.
-
Alpha-Ketoglutarate in Metabolic-Immune Assays
2026-08-17
Explore how alpha-ketoglutarate connects TCA-cycle flux, nitrogen handling, and macrophage function. This practical guide translates recent cholangiocarcinoma findings into better metabolite, enzyme, and metabolic reprogramming assay decisions.
-
HBTU Chemistry for Enzyme-Responsive Peptides
2026-08-17
HBTU is a versatile peptide coupling reagent for controlled carboxylic acid activation and peptide bond formation. This article connects its reaction chemistry to assay design for dual enzyme-responsive peptide amphiphiles while separating synthesis evidence from biological conclusions.
-
Omeprazole (A2845): Gastric Acid Research Guide
2026-08-16
Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research and related antiulcer activity study workflows. Because it is insoluble in water and ethanol and long-term solution storage is not recommended, researchers should prepare fresh DMSO-based solutions and use the compound only for scientific research, not diagnostic or medical applications.
-
Fosinopril Sodium in Translational Cardiovascular Research
2026-08-15
Fosinopril sodium offers translational researchers a mechanistically defined way to connect ACE inhibition with blood pressure reduction, renal hemodynamics, and cardiac remodeling. This thought-leadership perspective explains how its prodrug biology, phosphinic acid zinc binding, dual elimination, and formulation constraints should shape experimental design and cardiovascular disease model selection.
-
A-769662: Reversible AMPK Activator
2026-08-14
A-769662 is a reversible AMPK activator that increases AMPK signaling through allosteric activation and reduced Thr-172 dephosphorylation. It supports studies of energy metabolism regulation, fatty acid synthesis inhibition, and AMPK-independent proteasome inhibition, but its effects remain assay- and context-dependent.
-
Dorsomorphin (Compound C) AMPK Workflow Guide
2026-08-14
Dorsomorphin, also called Compound C, provides a reversible way to test whether AMPK signaling drives metabolic, endothelial, autophagic, or differentiation phenotypes. This practical guide translates a hypertension-cell study into assay-ready workflows while showing how to manage its parallel BMP/SMAD activity, solubility constraints, and interpretation risks.
-
AmpC/AmpD Resistance to Ceftolozane-Tazobactam
2026-08-13
Deroche and colleagues used engineered Pseudomonas aeruginosa mutants, sequential time-kill experiments, and semi-mechanistic PKPD modeling to separate the immediate and adaptive effects of ampC and ampD mutations. Their results show that the combined AmpC G183D and AmpD H157Y changes substantially reduced ceftolozane-tazobactam susceptibility while influencing imipenem adaptation in a different direction.
-
Omeprazole (A2845) Research Workflow Guide
2026-08-13
Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor reference for gastric acid secretion research, antiulcer activity studies, and related assay development. This guide covers identity checks, DMSO stock handling, assay controls, and interpretation limits; the compound is for scientific research only and not for diagnostic, therapeutic, or medical use.
-
Cefotaxime as a Probe of Resistance Architecture
2026-08-12
Cefotaxime offers more than a selectable antibiotic in antimicrobial resistance research: it can help connect beta-lactam phenotype, gene mobility, and bacterial infection model design. This article explains how to use Cefotaxime without overinterpreting susceptibility results, drawing on recent carbapenem-resistant Enterobacter cloacae research.
-
TCAIM Regulation of OGDH and Mitochondrial Metabolism
2026-08-12
Wang and colleagues identify TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. The study links mitochondrial proteostasis to post-translational control of a rate-limiting TCA-cycle enzyme, showing consequences for OGDH complex activity and carbohydrate catabolism in cells and mice.
-
Aurora Kinase A in High-Risk Retinoblastoma
2026-08-11
A 2024 study links elevated Aurora kinase A (AURKA) expression with histopathologic high-risk features in human retinoblastoma and shows that retinoblastoma models depend on functional AURKA. Its integrated tissue, genetic, pharmacologic, and xenograft evidence supports AURKA as a target for mechanistic studies of aggressive or chemotherapy-refractory disease.